Chinook Therapeutics Inc
NASDAQ:KDNY
Earnings Announcements
Chinook Therapeutics Reports First Quarter 2022 Results
Published: 05/12/2022 20:10 GMT
Chinook Therapeutics Inc (KDNY) - Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results.
Q1 Revenue $2.7 Million.
Qtrly Net Loss per Share Attributable to Common Stockholders, Basic and Diluted $0.54.
Q1 Revenue $2.7 Million.
Qtrly Net Loss per Share Attributable to Common Stockholders, Basic and Diluted $0.54.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.66
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.58
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.66
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.58
More details on our Analysts Page.